SHANGHAI, Aug. 1, 2022 — The closing of the Series B funding, totaling more than USD 120 million, has been announced by OriCell Therapeutics (Shanghai) Co., Ltd. (“OriCell” or “the Company”). Leading Chinese and foreign investment funds, as well as current stakeholder C&D Emerging Capital, participated in this round of funding, which Qiming Venture Partners and Quan Capital jointly led.
The additional money will be used to build a manufacturing facility that can be used for both clinical and commercial reasons, as well as to develop OriCell’s cell therapy pipeline and the company’s exclusive discovery platform.
Helen Yang, Chairman, and CEO of OriCell:
“We appreciate all of our new and old investors for continuing to support OriCell. We have continued to improve our senior management team while achieving several noteworthy milestones in the clinical development of our CAR-T and joint bispecific antibody programs. We anticipate delivering further ground-breaking scientific advancements and clinical breakthroughs in the next three years. We strive to build a world-leading cell treatment firm with a broad vision that can integrate effortlessly into the global market in China today’s open, welcoming, and innovative pharmaceutical environment.”
More about the startup:
OriCell Therapeutics, established in 2015, aspires to provide innovative immunotherapies to meet unmet clinical needs worldwide. OriCell has developed four adaptable and patent-protected technology platforms: Ori®Ab, a platform for antibody discovery; Ori®CAR, a CAR-T platform with high memory and vitality; Ori®TIL, a platform for stable and controllable cell culture for effective expansion; and Ori®UCAR, a platform for universal, practical, and effective CAR-T technology.
The National Medical Products Administration (NMPA) of China accepted OriCell’s Investigational New Drug (IND) submission for Ori-C101 in June of this year. Ori-C101 is the company’s first internally generated CAR-T product targeting GPC3 for treating advanced liver cancer.
Ori-C101 showed improved safety and performance in patients with GPC3-positive advanced liver cancer, with an objective response rate (ORR) of 44% and disease control rate (DCR) of 78%, according to results presented at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. Additional follow-ups are still being conducted, with the most extended follow-up lasting more than 22 months.
2019 saw the conclusion of an exclusive global license agreement between Antengene and Ori®Bs-001 (ATG101). A PD-L/4-1BB bispecific antibody called Ori®Bs-001 (ATG101) got implied clearance from the Center for Drug Evaluation (CDE) in China in March of this year after receiving INDs from the Australian Therapeutic Goods Administration and the U.S. Food and Drug Administration (TGA).
Dr. Weidong Cui joined the organization as Chief Technology Officer in March of this year. Dr. Cui has more than 20 years of expertise developing processes, producing cell therapy medicinal products under GMP standards, and running commercial operations. He was the former CTO at Fosun Kite and successfully oversaw the team’s completion of the first drug’s GMP production, IND registration, and NDA registration.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!